Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study
Jing Li,Ju Gao,Ansheng Liu,Wei Liu,Hao Xiong,Changda Liang,Yongjun Fang,Yunpeng Dai,Jingbo Shao,Hui Yu,Lingzhen Wang,Li Wang,Liangchun Yang,Mei Yan,Xiaowen Zhai,Xiaodong Shi,Xin Tian,Xiuli Ju,Yan Chen,Jing Wang,Leping Zhang,Hui Liang,Sen Chen,Jingrong Zhang,Haixia Cao,Jiao Jin,Qun Hu,Junlan Wang,Yilin Wang,Min Zhou,Yueqin Han,Rong Zhang,Weihong Zhao,Xiaoli Wang,Limin Lin,Ruidong Zhang,Chao Gao,Liting Xu,Yuanyuan Zhang,Jia Fan,Ying Wu,Wei Lin,Jiaole Yu,Peijing Qi,Pengli Huang,Xiaoxia Peng,Yaguang Peng,Tianyou Wang,Huyong Zheng,for the Chinese Children's Leukemia Group
DOI: https://doi.org/10.1200/jco.22.02836
IF: 45.3
2023-08-04
Journal of Clinical Oncology
Abstract:PURPOSE Homoharringtonine (HHT) is commonly used for the treatment of Chinese adult AML, and all-trans retinoic acid (ATRA) has been verified in acute promyelocytic leukemia (APL). However, the efficacy and safety of HHT-based induction therapy have not been confirmed for childhood AML, and ATRA-based treatment has not been evaluated among patients with non-APL AML. PATIENTS AND METHODS This open-label, multicenter, randomized Chinese Children's Leukemia Group-AML 2015 study was performed across 35 centers in China. Patients with newly diagnosed childhood AML were first randomly assigned to receive an HHT-based (H arm) or etoposide-based (E arm) induction regimen and then randomly allocated to receive cytarabine-based (AC arm) or ATRA-based (AT arm) maintenance therapy. The primary end points were the complete remission (CR) rate after induction therapy, and the secondary end points were the overall survival (OS) and event-free survival (EFS) at 3 years. RESULTS We enrolled 1,258 patients, of whom 1,253 were included in the intent-to-treat analysis. The overall CR rate was significantly higher in the H arm than in the E arm (79.9% v 73.9%, P = .014). According to the intention-to-treat analysis, the 3-year OS was 69.2% (95% CI, 65.1 to 72.9) in the H arm and 62.8% (95% CI, 58.7 to 66.6) in the E arm ( P = .025); the 3-year EFS was 61.1% (95% CI, 56.8 to 65.0) in the H arm and 53.4% (95% CI, 49.2 to 57.3) in the E arm ( P = .022). Among the per-protocol population, who received maintenance therapy, the 3-year EFS did not differ significantly across the four arms (H + AT arm: 70.7%, 95% CI, 61.1 to 78.3; H + AC arm: 74.8%, 95% CI, 67.0 to 81.0, P = .933; E + AC arm: 72.9%, 95% CI, 65.1 to 79.2, P = .789; E + AT arm: 66.2%, 95% CI, 56.8 to 74.0, P = .336). CONCLUSION HHT is an alternative combination regimen for childhood AML. The effects of ATRA-based maintenance are comparable with those of cytarabine-based maintenance therapy.
oncology